• Molecular NameAminolevulinic_acid
  • SynonymALA; Aminolevulinate; delta-Aminolevulinic acid
  • Weight131.131
  • Drugbank_IDDB00855
  • ACS_NO106-60-5
  • Show 3D model
  • LogP (experiment)-1.363
  • LogP (predicted, AB/LogP v2.0)-2.66
  • pkaN/A
  • LogD (pH=7, predicted)-5.16
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.23
  • LogSw (predicted, AB/LogsW2.0)738.88
  • Sw (mg/ml) (predicted, ACD/Labs)58.94
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds4
  • TPSA80.39
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIt is used to visualise tumorous tissue in neurosurgical procedures. Studies have shown that the intraoperative use of this guiding method may reduce the tumour residual volume and prolong progression-free survival in patients suffering from this disease. dALA or 5ala is also a photosensitizer for photodynamic therapy.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability55.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFollowing topical administration, synthesis into protoporphyrin IX takes place in situ in the skin.
  • Half life0.7h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A